The second generation of EORTC-ICIG experimental screening for systemic immunity adjuvants: Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract
- 30 November 1975
- journal article
- research article
- Published by Elsevier
- Vol. 11 (11) , 801-807
- https://doi.org/10.1016/0014-2964(75)90174-7
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Immune manipulation by BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukaemiaPublished by Elsevier ,1974
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973
- Effects of BCG on various facets of the immune response against polyoma tumors in ratsInternational Journal of Cancer, 1973
- Water-soluble and Lipid-free Fraction from BCG with Adjuvant and Antitumour ActivityNature New Biology, 1972
- Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration ComparedAnnals of Internal Medicine, 1972
- Possible Role of Macrophage Mediated Nonspecific Cytotoxicity in Tumour ResistanceNature New Biology, 1972
- Treatment of Acute Lymphoblastic Leukaemia: PRELIMINARY REPORT BY THE LEUKAEMIA COMMITTEE AND THE WORKING PARTY ON LEUKAEMIA IN CHILDHOODBMJ, 1971
- TUMOUR GROWTH IN NEMATODE-INFECTED ANIMALSThe Lancet, 1971
- Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells.British Journal of Cancer, 1969
- ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1969